Back to Journals » Degenerative Neurological and Neuromuscular Disease » Volume 4

Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA

Authors Ethans K, Casey A, Bard R, Namaka M

Received 16 November 2013

Accepted for publication 16 January 2014

Published 18 March 2014 Volume 2014:4 Pages 65—73

DOI https://doi.org/10.2147/DNND.S40349

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

KD Ethans,1,2 AR Casey,1,2 RJ Bard,1,3 MP Namaka1

1University of Manitoba, 2Section of Physical Medicine and Rehabilitation, Health Sciences Centre, 3Section of Urology, Health Sciences Centre, Winnipeg, Manitoba, Canada

Abstract: People with neurogenic overactive bladder from either multiple sclerosis or spinal cord injury often suffer significant morbidity and decreased quality of life. Here we review the pathophysiology of neurogenic overactive bladder and the impact it can have on people with multiple sclerosis or spinal cord injury. We also address the various traditional treatment options and focus on the use of botulinum toxin A (specifically onabotulinumtoxinA) for this condition.

Keywords: neurogenic detrusor overactivity, overactive bladder, onabotulinumtoxinA, multiple sclerosis, spinal cord injury

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012